Antihypertensive drug of the calcium channel blocker class
| Identifiers |
|---|
O5-methyl O3-[(3R)-1-(phenylmethyl)piperidin-3-yl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
|
| CAS Number | - 105979-17-7
 Y
|
|---|
| PubChem CID | |
|---|
| ChemSpider | - 571013
 N
|
|---|
| UNII | |
|---|
| ChEMBL | - ChEMBL2218858 N
|
|---|
| Chemical and physical data |
|---|
| Formula | C28H31N3O6 |
|---|
| Molar mass | 505.571 g·mol−1 |
|---|
| 3D model (JSmol) | |
|---|
|
InChI=1S/C28H31N3O6/c1-18-24(27(32)36-3)26(21-11-7-12-22(15-21)31(34)35)25(19(2)29-18)28(33)37-23-13-8-14-30(17-23)16-20-9-5-4-6-10-20/h4-7,9-12,15,23,26,29H,8,13-14,16-17H2,1-3H3/t23-,26-/m1/s1 NKey:QZVNQOLPLYWLHQ-ZEQKJWHPSA-N N
|
| NY (what is this?) (verify) |
Benidipine is a dihydropyridine calcium channel blocker for the treatment of high blood pressure (hypertension). It is a triple L-, T-, and N-type calcium channel blocker. It is reno- and cardioprotective.
It was patented in 1981 and approved for medical use in 1991.[1]
Dosing
Benidipine is dosed as 2–8 mg once daily.[2]
Mechanism
Benidipine is a calcium channel blocker.
Benidipine has additionally been found to act as an antagonist of the mineralocorticoid receptor, or as an antimineralocorticoid.[3]
Names
Other names include Benidipinum or benidipine hydrochloride.
Benidipine is sold as Coniel by Kyowa Hakko Kogyo.
Benidipine is initially licensed for use in Japan and selected Southeast Asian countries and later in Turkey, where it is sold as 4 mg tablets.
References
- ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 465. ISBN 9783527607495.
- ^ Hi-Eisai Pharmaceutical, Inc. "Coniel (benidipine) package insert (Philippines)". MIMS Philippines. CMPMedica. Retrieved 2008-03-31.
- ^ Luther JM (September 2014). "Is there a new dawn for selective mineralocorticoid receptor antagonism?". Current Opinion in Nephrology and Hypertension. 23 (5): 456–61. doi:10.1097/MNH.0000000000000051. PMC 4248353. PMID 24992570.
Ion channel modulators
| Calcium | | VDCCsTooltip Voltage-dependent calcium channels | |
|---|
|
|---|
| Potassium | | VGKCsTooltip Voltage-gated potassium channels | |
|---|
| IRKsTooltip Inwardly rectifying potassium channel | | Blockers | |
|---|
| Activators | - GIRKTooltip G protein-coupled inwardly rectifying potassium channel-specific: ML-297 (VU0456810)
|
|---|
|
|---|
| KCaTooltip Calcium-activated potassium channel | |
|---|
| K2PsTooltip Tandem pore domain potassium channel | |
|---|
|
|---|
| Sodium | | VGSCsTooltip Voltage-gated sodium channels | |
|---|
| ENaCTooltip Epithelial sodium channel | |
|---|
| ASICsTooltip Acid-sensing ion channel | |
|---|
|
|---|
| Chloride | | CaCCsTooltip Calcium-activated chloride channel | |
|---|
| CFTRTooltip Cystic fibrosis transmembrane conductance regulator | |
|---|
| Unsorted | |
|---|
|
|---|
| Others | | TRPsTooltip Transient receptor potential channels | |
|---|
| LGICsTooltip Ligand gated ion channels | |
|---|
|
|---|
See also: Receptor/signaling modulators • Transient receptor potential channel modulators |
|
|---|
| MRTooltip Mineralocorticoid receptor | |
|---|
- See also
- Receptor/signaling modulators
- Mineralocorticoids and antimineralocorticoids
- Glucocorticoid receptor modulators
- List of corticosteroids
|
N
Y (what is this?) (verify)
